**S2 Table. MVA-BN-HER2 synergized with PD-1 to delay tumor growth.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **MVA-BN-HER2 (Inf.U)** | **anti-PD-1 (µg)** | **Tumor Growth Inhibition (%)** | **Combination Index (CI)** | **Description** |
| 0 | 0 | 0.0 |  |  |
| 1.00E+05 | 0 | 6.7 |  |  |
| 1.00E+06 | 0 | 32.8 |  |  |
| 1.00E+07 | 0 | 45.9 |  |  |
| 1.00E+07 | 0 | 71.4 |  |  |
| 0 | 22 | 28.3 |  |  |
| 0 | 66 | 14.1 |  |  |
| 0 | 200 | 61.2 |  |  |
| 1.00E+07 | 22 | 61.9 | 0.496 | Synergism |
| 1.00E+07 | 66 | 89.3 | 0.031 | Very Strong Synergism |
| 1.00E+07 | 200 | 84.1 | 0.114 | Strong Synergism |

BALB/c mice were implanted with CT26-HER-2 cells on day 1 (i.d.) and treated with MVA-BN-HER2 and anti-PD-1 at doses indicated in the tables. Tumor growth inhibition was calculated from the untreated control. A combination index was calculated with the using the Chou-Talalay method and CompuSyn Software.